Handelsbanken Fonder AB Takes $2.91 Million Position in Qiagen N.V. $QGEN

Handelsbanken Fonder AB purchased a new position in shares of Qiagen N.V. (NYSE:QGEN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 74,401 shares of the company’s stock, valued at approximately $2,909,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of QGEN. United Services Automobile Association purchased a new position in Qiagen during the first quarter worth about $239,000. Prudential Financial Inc. raised its stake in shares of Qiagen by 74.9% in the 2nd quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock valued at $426,000 after acquiring an additional 3,799 shares during the period. Invesco Ltd. raised its stake in shares of Qiagen by 123.7% in the 2nd quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock valued at $48,350,000 after acquiring an additional 556,387 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Qiagen by 226.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock worth $125,000 after acquiring an additional 1,802 shares during the last quarter. Finally, First Trust Advisors LP acquired a new position in shares of Qiagen in the 2nd quarter worth approximately $3,639,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently weighed in on QGEN. Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 target price on shares of Qiagen in a report on Thursday, August 6th. TD Cowen restated a “hold” rating on shares of Qiagen in a research note on Wednesday, July 15th. Kepler Capital Markets set a $38.60 price target on Qiagen and gave the stock a “hold” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. raised their price target on Qiagen from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Zacks Research raised Qiagen from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Qiagen currently has an average rating of “Hold” and an average price target of $43.93.

Qiagen Trading Down 0.0%

Shares of QGEN stock opened at $42.94 on Monday. Qiagen N.V. has a fifty-two week low of $32.53 and a fifty-two week high of $57.81. The company has a 50 day moving average price of $40.09 and a 200 day moving average price of $41.23. The stock has a market capitalization of $8.85 billion, a P/E ratio of 22.00, a price-to-earnings-growth ratio of 4.28 and a beta of 0.63. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The company had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same period in the prior year, the business earned $0.60 EPS. The firm’s quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities research analysts predict that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.